Literature DB >> 3709623

Ceftriaxone pharmacokinetics following multiple intramuscular dosing.

A A Holazo, I H Patel, R E Weinfeld, J J Konikoff, M Parsonnet.   

Abstract

The steady-state pharmacokinetics and tolerance of ceftriaxone after multiple i.m. doses of 0.5 and 1 g q12 h for 3.5 days were investigated in 12 healthy, adult volunteers. Ceftriaxone was rapidly absorbed after i.m. administration with mean peak times ranging from 1.3 to 1.9 h. Steady-state plasma concentrations were apparent after the third dose of both dosage regimens, with trough plasma concentrations of 24 +/- 6 and 39 +/- 8 micrograms/ml (mean +/- SD) after the 0.5 and 1 g q12 h regimens, respectively. Multiple i.m. administrations of ceftriaxone did not alter its elimination half-life; however, small increases were observed in the plasma clearance and volume of distribution at the 1-g regimen. These increases were attributed to the non-linear binding of ceftriaxone to human plasma proteins, and are therapeutically unimportant. Ceftriaxone was well tolerated and serious or lasting adverse reactions were not encountered in the study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709623     DOI: 10.1007/bf00614206

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Intramuscular injection of drugs.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

2.  A study of the relationship between dose and pharmacokinetics of ceftriaxone.

Authors:  C D Findlay; R M Brown; J E Allcock; P A Lowe; R Wise
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

3.  A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic.

Authors:  M E Pickup; H A Bird; J R Lowe; L Lees; V Wright
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

4.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

5.  Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents.

Authors:  I H Patel; R E Weinfeld; J Konikoff; M Parsonnet
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

6.  Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.

Authors:  B R Meyers; E S Srulevitch; J Jacobson; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

7.  Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers.

Authors:  R Delsignore; C M Baroni; G Crotti; F Mineo; U Butturini; V Ascalone; M Cisternino
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

8.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

9.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

10.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

View more
  4 in total

Review 1.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 3.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.